Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation-Reference-Cited by-同舟云学术

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

Published:2014-06 Issue:6 Volume:38 Page:756-767
ISSN:0147-5185
Container-title:American Journal of Surgical Pathology
language:en
Short-container-title:

Author:

Epstein Jonathan I.,Amin Mahul B.,Beltran Himisha,Lotan Tamara L.,Mosquera Juan-Miguel,Reuter Victor E.,Robinson Brian D.,Troncoso Patricia,Rubin Mark A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pathology and Forensic Medicine,Surgery,Anatomy

Reference27 articles.

1. Neuroendocrine cells in tumour growth of the prostate.;Abrahamsson;Endocr Relat Cancer,1999

2. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate.;Bonkhoff;Virchows Arch A Pathol Anat Histopathol,1993

3. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium.;Azzopardi;J Pathol,1971

4. Argentaffin and argyrophil cells in the prostate.;Kazzaz;J Pathol,1974

5. Neuroendocrine differentiation in prostatic carcinoma.;Abrahamsson;Prostate,1999

Cited by 443 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

2. A case of mixed neuroendocrine carcinoma–acinar adenocarcinoma: Utilization of triplet therapy for prostate cancer;IJU Case Reports;2024-09

3. Divergences in neuroendocrine prostate cancer frequency as recognized by anatomic pathologists, clinicians, and basic scientists;Asian Journal of Andrology;2024-08-20

4. Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer;Nature Communications;2024-08-05

5. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial;The Lancet Oncology;2024-08